Bank of America began coverage on shares of Finch Therapeutics Group (NASDAQ:FNCH) in a research note issued to investors on Monday, Benzinga reports. The firm issued a buy rating and a $25.00 price target on the stock.
A number of other equities analysts also recently commented on the company. Jefferies Financial Group initiated coverage on Finch Therapeutics Group in a report on Monday. They set a buy rating and a $29.00 target price for the company. Evercore ISI initiated coverage on Finch Therapeutics Group in a report on Monday. They set an outperform rating and a $34.00 target price for the company.
Shares of Finch Therapeutics Group stock opened at $13.96 on Monday. Finch Therapeutics Group has a 52 week low of $13.44 and a 52 week high of $22.50.
Finch Therapeutics Group Company Profile
Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, engages in developing a novel class of orally administered biological drugs in the United States. Its lead candidate is CP101, an orally administered microbiome capsule that has completed Phase II clinical trial for the treatment of patients with recurrent Clostridioides difficile infection.
Featured Story: How to start trading in the forex market?
Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.